Stockscreener 앱 받기
2.90
3.01%
-0.09
시장 영업 전:
2.82
-0.08
-2.76%
Cyclerion Therapeutics Inc 주식(CYCN)의 최신 뉴스
Cyclerion Therapeutics (NASDAQ:CYCN) Shares Up 3.5% – Time to Buy? - Defense World
Looking Into Cyclerion Therapeutics's Recent Short Interest - Benzinga
Extended Session Gains Propel Cyclerion (CYCN) Amid Revenue Progress - Stocks Telegraph
Cyclerion Therapeutics (NASDAQ: CYCN) Amends License Agreement with Akebia Therapeutics and Generates Revenues for GrowthOn December 17, 2024, Cyclerion Therapeutics, Inc. filed an 8-K SEC Filing which detailed significant developments in its b - Defense World
Cyclerion advances growth strategy with new agreements - Investing.com
Cyclerion Therapeutics Secures Funding and Expands CNS Focus - TipRanks
Cyclerion advances growth strategy with new agreements By Investing.com - Investing.com UK
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth - GlobeNewswire
Cyclerion Strikes $560M Milestone Deal with Akebia, Completes Portfolio Monetization Strategy - StockTitan
Head to Head Survey: Cyclerion Therapeutics (NASDAQ:CYCN) vs. scPharmaceuticals (NASDAQ:SCPH) - Defense World
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update - Defense World
3 US Penny Stocks With Market Caps Under $100M - Simply Wall St
Cyclerion stock hits 52-week high at $5.25 amid market fluctuations - Investing.com Canada
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69% - Investing.com
Stock market news: Cyclerion Therapeutics +280.50%, Cross Country Healthcare +62.01% among top gainers during mid day trading - Business Upturn
Stock market news: Relmada Therapeutics plunged by 75.54% while Cyclerion Therapeutics surged by 280.12% during mid day trading - Business Upturn
Stock market today: Cyclerion Therapeutics +343.79%, Cross Country Healthcare +63.04% among top gainers in early trading - Business Upturn
Stock market today: Relmada Therapeutics declined by 74.74% while Cyclerion Therapeutics saw surge of 392.22% in early trading - Business Upturn
Cyclerion stock hits 52-week high at $5.25 amid market fluctuations By Investing.com - Investing.com South Africa
Why Nutanix Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket - Benzinga
CYCN (Cyclerion Therapeutics) 3-Year EBITDA Growth Rate : 57.30% (As of Sep. 2024) - GuruFocus.com
CYCN (Cyclerion Therapeutics) GF Value Rank : 5 (As of Nov. 25, 2024) - GuruFocus.com
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cyclerion stock hits 52-week low at $1.55 amid market challenges - Investing.com Canada
Cyclerion stock hits 52-week low at $1.55 amid market challenges By Investing.com - Investing.com South Africa
Cyclerion Therapeutics Inc (CYCN) Quarterly 10-Q Report - Quartzy
Cyclerion Therapeutics stock hits 52-week low at $1.75 By Investing.com - Investing.com South Africa
Cyclerion Therapeutics stock hits 52-week low at $1.75 - Investing.com India
Where Are They Now? Ironwood Pharmaceuticals - Life Science Leader Magazine
Vascular Dementia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Charsire Biotech Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP - Barchart
cyclerion therapeutics, inc. Earnings dates - RTTNews
Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 8.1% - Defense World
Analyzing Cyclerion Therapeutics (NASDAQ:CYCN) and Seelos Therapeutics (NASDAQ:SEEL) - Defense World
Cyclerion appoints Regina Graul as CEO and President - Investing.com
Cyclerion Therapeutics Promotes Regina Graul, Ph.D., to Chief Executive Officer - citybiz
Regina Graul, Ph.D., Promoted to Chief Executive Officer - StreetInsider.com
Short Interest in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Expands By 10.9% - Defense World
Cyclerion Therapeutics - BioSpace
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer - Marketscreener.com
Cyclerion Appoints Regina Graul, Ph.D., as President - citybiz
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - GlobeNewswire
Cyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With Losses - Yahoo Finance
Cyclerion in Talks on Buyout Proposal for Drug Assets; CEO Offers to Make Equity Investment - Marketscreener.com
Rapport Therapeutics Appoints Chief Operating Officer and Scientific Advisory Board Member - Business Wire
Tisento Therapeutics Raises $81M in Series A - citybiz
Tisento Therapeutics Raises $81M in Series A Funding - FinSMEs
Bio Startup Tisento Launches With $81M and a Brain-Penetrating Drug in the Clinic - MedCity News
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Cyclerion Announces Reverse Stock Split - Yahoo Finance
Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors - Yahoo Finance
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 - GlobeNewswire
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement - GlobeNewswire
Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as Chief Scientific Officer - Business Wire
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results - Yahoo Finance
4.81%
자본화:
|
볼륨(24시간):